RTTNews | Jan 25, 2022 10:07AM EST

10:07 Tuesday, January 25, 2022 (RTTNews.com) - Shares of vaccine manufacturer BioNTech SE (BNTX) are rising 5 percent on Tuesday's trading after the company and its partner Pfizer Inc. (PFE) announced the initiation of a clinical trial to evaluate an Omicron-based vaccine candidate in adults aged between 15 and 55 years.

In a statement, the companies said that the study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine. The first participants enrolled in the study have received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose, they added.

Currently at $159.82, the stock has traded between $90.29 and $464.00 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3257097/biontech-shares-rise-5-on-announcement-of-omicron-vaccine-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved